Table 1. Patient characteristics of the derivation and validation cohorts.
|
No. (%)a |
||
|---|---|---|
| Variable | Derivation (n=228) | Validation (n=87) |
|
Age, years | ||
| Mean±s.d. | 62.5±13.1 | 62.1±14.3 |
| Age <65 years | 126 (55.3) | 51 (58.6) |
|
Sex | ||
| Male | 148 (64.9) | 62 (71.3) |
| Female | 80 (35.1) | 25 (28.7) |
|
Primary site | ||
| Cutaneous | 200 (87.7) | 68 (78.2) |
| Mucosal | 13 (5.7) | 11 (12.6) |
| Unknown | 15 (6.6) | 8 (9.2) |
|
M category (AJCC 2009) | ||
| Unresectable stage 3 | 4 (1.8) | 3 (3.4) |
| M1a | 42 (18.4) | 8 (9.2) |
| M1b | 49 (21.5) | 11 (12.6) |
| M1c | 133 (58.3) | 65 (74.7) |
|
ECOG performance status | ||
| 0 | 157 (68.9) | 75(86.2) |
| 1 | 65 (28.5) | 12 (13.8) |
| 2 | 5 (2.2) | 0 (0.0) |
| 3 | 1 (0.4) | 0 (0.0) |
|
LDH | ||
| Normalb | 150 (65.8) | 49 (56.3) |
| Elevatedc | 78 (34.2) | 38 (43.7) |
|
WBC | ||
| Mean±s.d. | 7.1±3.5 | 6.6±1.9 |
|
BRAF mutation status | ||
| Negative | 162 (72.0) | 56 (65.1) |
| Positive | 63 (28.0) | 30 (34.9) |
| Unknown | 3 (1.3) | 1 (1.1) |
|
Liver metastasis | ||
| No | 160 (70.2) | 66 (75.9) |
| Yes | 68 (29.8) | 21 (24.1) |
|
Lung metastasis | ||
| No | 96 (42.1) | 46 (52.9) |
| Yes | 132 (57.9) | 41 (47.1) |
|
Brain metastasis | ||
| No | 178 (78.1) | 71 (81.6) |
| Yes | 50 (21.9) | 16 (18.4) |
|
Previous ipilimumab treatment | ||
| No | 81 (35.5) | 46 (52.9) |
| Yes | 147 (64.5) | 41 (47.1) |
|
Previous targeted therapy | ||
| No | 174 (76.3) | 68 (78.2) |
| Yes | 54 (23.7) | 19 (21.8) |
Abbreviations: AJCC=American Joint Committee on Cancer; ECOG=Eastern Cooperative Oncology Group; LDH=lactate dehydrogenase; WBC=white blood cell.
a
Values are reported as no. (%) unless otherwise indicated.
b
Defined as LDH ratio ⩽1.
c
Defined as LDH ratio >1.